1) Radiotherapy associated with Weimeng chemotherapy
联合威猛化疗
2) Combined chemotherapy
联合化疗
1.
The clinical observation of combined chemotherapy for advanced breast cancer.;
晚期乳腺癌联合化疗的临床观察
2.
Therapeutic Effect of Combined Chemotherapy on Head-Neck Malignant Tumors;
联合化疗在头颈部恶性肿瘤治疗中的作用
3.
Clinical study of Nasea with intravenous injection for combined chemotherapy induced gastrointestinal reaction in patients with malignant blood diseases;
奈西雅预防恶性血液病患者联合化疗所致胃肠反应的临床研究
3) chemotherapy
[英][,ki:məʊ'θerəpi] [美]['kimo'θɛrəpɪ]
联合化疗
1.
Therapy effect of chemotherapy combined with hyperthermia with endogenetic field tumor hyperthermia system in treatment of primary hepatic carcinoma;
内生场热疗联合化疗治疗原发性肝癌的临床观察
2.
Effect analysis of bone metastasis cured by Bonin with antineoplastic chemotherapy;
博宁联合化疗治疗骨转移癌的疗效分析
3.
Clinical observation of pingxiao capsule plus chemotherapy for the treatment of gastric cardia carcinoma;
平消胶囊联合化疗治疗贲门癌临床观察(附87例)
4) Combination chemotherapy
联合化疗
1.
Objective To evaluate the efficacy and safety of combination chemotherapy based on vinorebine in the treatment of patients with advanced esophgeal cancer.
目的观察以长春瑞滨为主的联合化疗方案治疗晚期食管癌的疗效和安全性。
2.
Objective:To observe the efficacy and adverse response of pirarubicin(THP,T)combination chemotherapy in Non-Hodgkin s lymphoma(NHL).
目的:观察吡喃阿霉素(THP)为主的联合化疗方案治疗非何杰金淋巴瘤的疗效及其毒副作用。
3.
Purpose:To evaluate the short-term effects and toxic side-effects of GEM plus CBP combination chemotherapy in treating advanced non-small-cell lung cancer(NSCLC).
目的 :观察吉西他滨 (GEM)加卡铂 (CBP)联合化疗治疗晚期非小细胞肺癌 (NSCLC)的近期疗效及毒副作用。
6) VM-26
威猛
1.
Clinical Analysis of Radiotherapy Associated with VM-26 and DDP Chemotherapy of 23 Cases with Cerebral Metastatic Carcinoma;
威猛加顺铂化疗配合放射治疗脑转移癌23例临床分析
补充资料：威猛
分子式：
CAS号：
性质：又名威猛。本品为中性亲脂性物质，几乎不溶于水，溶于有机溶剂。以从植物中提取的鬼臼毒素为原料，经缩合、还原、缩合而制得本品，为表鬼臼毒的半合成衍生物。为抗肿瘤药，作用为VP-16的5～10倍，与VP-16有交叉耐药。临床主要用于小细胞肺癌，急性淋巴白血病、神经母细胞瘤和淋巴瘤。
CAS号：
性质：又名威猛。本品为中性亲脂性物质，几乎不溶于水，溶于有机溶剂。以从植物中提取的鬼臼毒素为原料，经缩合、还原、缩合而制得本品，为表鬼臼毒的半合成衍生物。为抗肿瘤药，作用为VP-16的5～10倍，与VP-16有交叉耐药。临床主要用于小细胞肺癌，急性淋巴白血病、神经母细胞瘤和淋巴瘤。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条